Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose PK and safety study of subcutaneous otilimab in healthy Japanese adults
jRCT2071210132Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Primary endpoints: Cmax of otilimab and AUC(0-inf) of otilimab. Started Mar 2022; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2071210132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210132.